Objective. To identify the optimal dose of oral iloprost on the basis of efficacy and tolerability in patients with Raynaud's phenomenon secondary to systemic sclerosis.
R' phenomenon, which occurs in over 90% of Iloprost is a chemically stable prostacyclin analogue patients with systemic sclerosis, is often difficult to with potent vasodilatory effects [14] . It also has additreat [1] . In addition to very troublesome vasospasm, tional potentially useful properties of inhibiting platelet which appears to be the result of an imbalance of adhesion and aggregation, altering neutrophil function, vascular factors normally maintaining vessel tone, such including free-radical production by neutrophils and patients have a damaging proliferative structural vascuneutrophil adhesion to endothelial cells [15] , and it lar lesion [2] . The endothelial lesion, characteristic of has been hypothesized that it may speed the repair of scleroderma, is associated with evidence of immunedamaged endothelium. mediated damage [3] , in vivo platelet activation [4] Iloprost has been shown in previous studies to have and release of the vasoconstrictors serotonin and immediate and long-term benefits in the treatment of thromboxane [5, 6 ] , a decrease in the vasodilators Raynaud's when compared with placebo [16, 17] , and nitric oxide [7] and calcitonin gene-related peptide [8] , also to be as effective as nifedipine in a parallel group increased resistance to the vasodilator prostacyclin [9, trial [18] . It has also been shown to be effective against 10], free-radical generation [11, 12] and a leaky endovasospasm even when given in low dose [19] and can thelium which permits the egress of inflammatory cells produce significant healing of digital ulcers [20] . Its into the perivascular space [13] .
use in the treatment of Raynaud's has been restricted to date to patients with very severe disease because of the need for hospital admissions and i.v. infusions. An and doses were chosen from a dose titration study
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[21]. We describe the results of the first multicentre, © 1998 British Society for Rheumatology double-blind, placebo-controlled, parallel-group study time. The 50 mg group took one 50 mg iloprost capsule and one placebo capsule twice daily. The dose in the of two doses of oral iloprost in 103 patients with Raynaud's phenomenon secondary to systemic oral iloprost 100 mg group was titrated so that patients took one 50 mg iloprost capsule and one placebo capsclerosis.
sule twice daily for the first week, and the full dose of METHODS two 50 mg iloprost capsules twice daily for the remaining 5 weeks. Thus, all patients took two capsules
Patients
Patients with Raynaud's phenomenon secondary to twice daily for 6 weeks, maintaining the double-blind nature of the study. systemic sclerosis were recruited from out-patient clinics at seven university hospitals in Denmark Allocation to a treatment group was carried out by assigning to the patient the next available random-(two centres), Great Britain (three centres) and The Netherlands (two centres). Raynaud's phenomenon ization number in the sequence given to the centre. Each randomization number corresponded to a numwas diagnosed on the basis of a history of episodic digital pallor and cyanosis. Systemic sclerosis was bered set of study medication. The sequence of treatments in the randomization list was determined by a diagnosed according to the criteria of the American College of Rheumatology [22] with the addition that computer-generated random sequence in balanced blocks of four. Each centre received separate sequences abnormal nailfold capillaries were permitted as one of the signs. In order to be randomized into the study, of randomization numbers for patients with ulcers and patients without ulcers in order to achieve a balanced patients had to have an average of at least six Raynaud's attacks per week in the 2 week prerandomization stratified by centre and presence of digital cutaneous lesions. treatment assessment period, documented by patient diary.
Males and females were included and all patients
Study design
The study consisted of three periods: a 2 week prewere at least 18 yr old. Women of child-bearing age were required to practise a medically acceptable treatment period, a 6 week treatment period and a 6 week post-treatment follow-up. Randomization to one method of birth control, and to have a negative pregnancy test at the beginning and end of the preof three treatments occurred on satisfactory completion of the pre-treatment period. The treatment and followtreatment assessment period.
Patients were excluded from participation if they up periods were double blind. Patients visited the clinics 1, 2, 4, 6, 8 and 12 weeks after the start of fulfilled any of the following criteria: treatment with any prostanoid for vascular disease in the previous 2 treatment. Patients were assessed for the full 12 weeks after the start of treatment irrespective of whether the months; surgical sympathectomy performed in the previous 12 months; bleeding diathesis or a platelet treatment was taken for the full 6 weeks or not. All patients were recruited during the months of January disorder; stroke, transient ischaemic attack or myocardial infarction within the past 6 months; or onset and February. of renal insufficiency in the previous 4 weeks.
Administration of other drugs for the treatment of Clinical outcome variables Patients were given specially designed diaries to Raynaud's phenomenon was not allowed for the duration of the study. Drugs for the treatment of the be completed daily throughout the study even if the treatment was discontinued prematurely ( Fig. 1 ). underlying systemic sclerosis were not initiated or terminated during the study period. Vasodilators for Diaries were provided in the native language of the patient: Danish, Dutch or English, as appropriate. the treatment of hypertension were maintained at a constant dose throughout the study.
Each day, patients recorded the number of Raynaud's attacks, the duration of each attack and an assessment The study protocol was approved by the appropriate ethics committees for each trial centre and all patients of the overall severity of their condition on a scale of 0-10, the Raynaud's Condition Score ( RCS). An provided written informed consent to their participation in the study.
attack was defined as an episode of pallor followed by cyanosis with or without associated pain. The mean daily number of Raynaud's attacks for Treatments Iloprost was supplied as an extended-release formueach patient was calculated for each 2 week interval throughout the study. The mean total daily duration lation consisting of hard gelatin capsules containing 50 mg iloprost in the form of iloprost-b-cyclodextrin of attacks for each 2 week interval was calculated for each patient by adding the individual attack durations clathrate. Placebo capsules were identical in appearance and contained the same excipients.
for the interval and dividing by the number of diary days. The mean of the daily RCS was also calculated Patients took one of three treatments: placebo, oral iloprost 50 mg or oral iloprost 100 mg twice daily for 6 for each 2 week interval. Mean weekly outdoor temperatures were determined weeks, giving total daily doses of 0, 100 and 200 mg iloprost, respectively, in the three treatment groups.
for each patient from data provided by the local meteorological centres for each participating centre. Capsules were taken twice daily with food with a 5 h interval between doses. The placebo group took two Mean changes were calculated for each patient group. The physician's global assessment of the patient's placebo capsules at breakfast and two more at lunch-F. 1.-Specimen treatment diary. This diary record was completed by all subjects to assess the severity and frequency of their Raynaud's symptoms, as outlined in the text.
condition compared to pre-treatment was recorded 6 forward (LOCF ) principle in order to investigate possible bias due to missing information. weeks after the start of treatment. Each patient was classified as being worse, unchanged or improved comTreatment differences in the efficacy parameters total daily duration, frequency and severity of Raynaud's pared to baseline.
Digital cutaneous lesions were recorded before the attacks were determined by use of a two-way analysis of variance on the percentage change from baseline. start of treatment and at 6 and 12 weeks after the start of treatment. The total number of lesions on the hands
The two-way model incorporated treatment, baseline lesion status and treatment × baseline lesion status as was recorded, and the number of each type classified as ulcers, fissures and paronychiae.
an interaction term. Ordinal variables, such as the physician's global assessment of efficacy, were tested for treatment differences using the Mantel-Haenszel Tolerability and safety
Patients were asked at each visit to the clinic to x2 test. Differences in frequencies of adverse events were tested by the Mantel-Haenszel test for trend in report any adverse events occurring in the interval since the previous visit. Systolic and diastolic blood proportions across the increasing doses. All tests were two tailed and run with a = 0.05. pressure and heart rate were measured at each visit while the patient was in a supine position. RESULTS Laboratory parameters were investigated before the start of treatment and at the end of treatment.
Of the 103 patients enrolled in the study, 35 were randomized to placebo, 33 to iloprost 50 mg and 35 to Haematology parameters measured were haematocrit, haemoglobin, erythrocyte count, leucocyte count and iloprost 100 mg. Eighty-nine patients (86%) completed diaries for the whole 6 week treatment period and 82 platelet count. Serum chemistry consisted of sodium, potassium, creatinine, alanine transaminase (ALT ) and patients (80%) for the 12 weeks of treatment plus follow-up. Twenty-one patients failed to complete all aspartate transaminase (AST ). Urinalysis consisted of dipstick analysis for protein, glucose and blood.
of the assessments up to 12 weeks: five on placebo, seven on iloprost 50 mg and nine on iloprost 100 mg.
Study medication was discontinued prematurely in 31 Statistical analysis
The results presented derive from an observed case patients: placebo, three patients (9%); iloprost 50 mg, 10 patients (30%); iloprost 100 mg, 18 patients (51%). analysis in which all patients randomized and all data recorded were included, but no attempt was made to
Of the patients who discontinued treatment early, 58% discontinued in the first 2 weeks: placebo, three impute values where data were missing. However, a secondary analysis of the diary parameters (total daily patients; iloprost 50 mg, seven patients; iloprost 100 mg, eight patients. All but two of the treatment discontinuaduration, frequency and severity of Raynaud's attacks) was also performed using the last observation carried tions were due to adverse events.
The demographic characteristics of the patients were Raynaud's condition score The RCS was very similar in all three groups before similar in the three treatment groups ( Table I ) . Seventy-seven patients (75%) were classified as having treatment. During and after treatment, reductions in the RCS appeared to show a dose relationship, with systemic sclerosis with limited skin involvement and 24 patients (22%) with diffuse skin involvement. Two the smallest reductions with placebo and the greatest with iloprost 100 mg (Fig. 4 ). There was a strong patients were unclassifiable in this respect. The distribution of the systemic sclerosis types was comparable in statistical trend towards a difference between the groups at weeks 5-6 (P = 0.07) and a significant the three treatment groups. Twenty-eight patients had some kind of digital cutaneous lesions at the start of difference at weeks 11-12 (P = 0.007) (Table IV ) . treatment, 22 of them had ulcers. These were also evenly distributed between the three treatment groups.
Statistical power and the effect of missing data The statistical power of the observed case analyses The prevalence of gastrointestinal and pulmonary involvement was similar in each group. Over 70% of of duration, frequency and RCS, calculated on the data obtained in the study, was 65, 30 and 72%, the patients in each group had received other medication for systemic sclerosis or Raynaud's phenomenon respectively, at weeks 5-6, and 97, 76 and 96%, respectively, at weeks 11-12. in the previous 12 months. None had received prostanoids in the previous 2 months and only three Analysis of the data from patient diaries was repeated using the LOCF principle in the case of patients has received prostanoids in the previous 3 months (iloprost 50 mg, two patients; iloprost 100 mg, missing data at the end of the planned treatment period. Using this method, the mean percentage one patient). Nine patients distributed across the three treatment groups received vasoactive treatment for changes in the total duration of attacks at weeks 5-6 were placebo 11%, iloprost 50 mg −40% and iloprost hypertension during the study, but doses were kept constant throughout the pre-treatment and follow-100 mg −39%, compared to mean percentage changes of 10, −40 and −35%, respectively, in the observed up periods.
case analysis. Other analyses also produced essentially similar results to those already described, suggesting Total daily duration of Raynaud's attacks that no significant bias resulted from the failure of During the pre-treatment period, the total duration some patients to complete the diaries. of attacks was lowest in the placebo group and highest with oral iloprost 100 mg ( Table II ) , but the difference Physician's global assessment was not significant. The two iloprost groups showed Improvement in the patient's condition tended to be similar reductions in the total duration at all time more likely with increasing dose of oral iloprost at the points ( Fig. 2) which were markedly greater than those end of the treatment period, placebo 44%, iloprost in the placebo group at weeks 5-6 (P = 0.03) and 50 mg 57%, and iloprost 100 mg 64%, but betweenweeks 11-12 (P = 0.001) ( Table II ) .
group differences were not significant. By the end of the follow-up period, at least 50% of the patients were Frequency of Raynaud's attacks considered by the physician to have improved in each Differences in the frequency of attacks between the treatment group, including placebo, and there were no treatment groups at baseline were not significant. The significant between-group differences. variability of the frequency of attacks was very high and, despite greater mean reductions in the two iloprost Digital cutaneous lesions groups, differences between the groups were not signiTwenty-eight patients had digital cutaneous lesions ficant at weeks 5-6 (P = 0.37) and showed a trend at on entry into the study (nine placebo, 10 iloprost 50 mg weeks 11-12 (P = 0.07) ( Fig. 3 and Table III ) . and nine iloprost 100 mg). Twenty-two of these patients had ulcers. The numbers of patients in whom ulcers healed for placebo, iloprost 50 mg and iloprost 100 mg were 1/7, 1/8 and 3/7, respectively. The numbers of The effects of placebo and two doses of oral iloprost on this variable shown (mean ± ...).
are shown (mean ± ...).
iloprost dose, while flu syndrome was most commonly reported in the placebo group ( Table V ) . Assessment of vital signs before and during treatment showed no ment and it was not felt necessary to open the treatment codes prematurely. clinically significant effects of either dose of iloprost on blood pressure or heart rate. Premature discontinuation due to adverse events appeared to be dose related:
Laboratory tests No trends were seen in any of the laboratory paraplacebo, two patients (6%); iloprost 50 mg, nine patients (27%); iloprost 100 mg, 18 patients (51%) meters and no individual changes during the study were attributed to the study medication. (P < 0.001).
There were no deaths during the study, but serious adverse events were reported in two patients. These
Outdoor temperatures The minimum and maximum outdoor temperatures were one patient on placebo who experienced an episode of faintness and palpitations due to atrial experienced by the patients in each treatment group were comparable during the pre-treatment period. The fibrillation, and one patient on oral iloprost 100 mg who experienced shortness of breath, lethargy, loss of changes in minimum and maximum daily temperatures recorded from baseline to the end of the 6 week weight and cough due to a pulmonary infection which was treated with a course of antibiotics. Neither of treatment (mean +1°C and +4°C, respectively) and from baseline to the end of 12 weeks follow-up (mean these were likely to have been caused by study treat- +5°C and +8°C, respectively) were almost identical (± <1°C ) in the three treatment groups. DISCUSSION Raynaud's phenomenon and the underlying systemic sclerosis currently both lack an effective treatment. Apart from a poor understanding of the vascular dysfunction, other factors which may contribute to the management problems often encountered include the paucity of well-controlled trials of many of the available vasoactive drugs, and the fact that many of the earlier studies evaluated patients with Raynaud's phenomenon of many different aetiologies within the same study. Not withstanding these difficulties, nifedipine has emerged as the most widely used oral medication for Raynaud's phenomenon, although there are many others which may be tried [23] . Such drugs can be very useful, but they may have troublesome side-effects and can be ineffective in severely affected patients, many of whom have secondary Raynaud's in associ- although considerably improved by dose reduction, is enhanced the observed treatment effect, by allowing a greater potential for improvement, or it could have also not without difficulties. The ideal would therefore be a drug as effective as i.v. prostanoids without the reduced the observed treatment effect if patients with more advanced disease are less amenable to treatment. side-effects. The present study describes the use of an orally active preparation of iloprost.
Use of percentage change should have reduced the likelihood of bias in this respect, and the RCS, which Our data show that both fixed-dose regimens of oral iloprost significantly reduce the total daily duration of was similar in all groups at baseline, also showed a significant treatment effect. Raynaud's attack at 5-6 weeks (the end of the treatment period) and at 11-12 weeks (6 weeks after the This study is the first to test a fixed-dose regime of iloprost. Both earlier oral iloprost studies [21] and i.v. therapy had ended). The duration of benefit is interesting as there appears to be a slow onset of effect which studies [17, 24] used titrated maximum tolerated doses in each patient. A further difference to the earlier oral continued to increase after the end of treatment. This is consistent with data from i.v. studies. The difference iloprost studies is that the present study tested for 6 weeks of treatment instead of 10 days. This, or a lack between iloprost and placebo continued to grow after treatment, which would strongly imply that this is not of statistical power in the previous studies, could explain the more convincing efficacy which this present just a seasonal temperature effect.
The variability in the frequency of attacks in the paper demonstrates. In the previous oral study, patient opinion tended to favour iloprost at the end of the 10 patient population was great, and despite a mean reduction in the two iloprost groups, there was no day treatment phase, and this was significant at day 24. However, the decrease in duration and severity of statistically significant difference at 5-6 weeks and only a trend at weeks 11-12. The size of the thermal or attacks in the iloprost group, although showing a trend, did not reach statistical significance. More emotional triggers which initiate a Raynaud's attack is highly variable, both within a Raynaud's population difficult to explain is the prolonged effectiveness of iloprost following a short i.v. course, which has been and within a single patient over time, and this may account in part for this particular result. The overall observed by several groups. It is possible that slight differences in the pharmacokinetic profile and the severity of the condition or the RCS, in contrast, showed not only a dose-dependent effect, the 100 mg ability to adjust the i.v. infusions more precisely to a maximum tolerated dose may make simple comparidose being the most effective, but also a statistical effect which became stronger with time. The P value sons of the duration of oral and i.v. treatments inappropriate. for the differences between the groups was 0.07 at weeks 5-6 and 0.007 at weeks 11-12. These results
The vasculopathy of systemic sclerosis is characterized histologically by abnormal vascular endothelium, may again reflect the 'repair' function of the drug.
The assessment of changes in Raynaud's attacks was intimal thickening and adventitial fibrosis, and clinically by vasospasm, pitting scars, telangiectasiae and based upon percentage changes as the changes relative to an individual's baseline are more meaningful than ulcers. The benefit of iloprost on vascular function may in part be explained by the capacity of iloprost an absolute change. This is particularly appropriate when, as in this study, baseline values vary considerto inhibit platelet activation, prevent leucocyte adherence to the endothelium to attenuate free-radical genably. The greater baseline frequency and total duration of Raynaud's attacks in the iloprost groups could have eration by neutrophils and possibly to repair for a period of time a damaged leaky endothelium [15] .
In conclusion, oral iloprost given twice daily for 6 weeks improved Raynaud's phenomenon symptoms in Rademaker et al. [18] suggested that a damaged endothelium in and of itself might contribute to vasospasm, patients with systemic sclerosis in this study. The improvement continued for 6 weeks after treatment and that cellular repair and restoration of full functional capacity might take longer than a few days, thus had ceased. Statistical trends became increasingly significant over the period of observation, suggesting a explaining the vascular effects and clinical improvement which continue weeks after treatment cessation. possible cumulative effect of the drug on endothelial cell function. The drug appeared to be effective at both A consistent feature of the three main endpoints recorded by the patients in the diaries was the low 50 mg twice daily and 100 mg twice daily with some evidence of a dose-response relationship. The 50 mg placebo response, never more than 15-20% improvement over baseline. This is in contrast to the assessment dose is preferred due to better tolerability and clinical acceptability, despite the headaches, and this dose is by the physicians that~40-50% of the patients had improved by the end of the treatment period. As is currently under study in order to establish its efficacy in a larger population. usual in Raynaud's studies, a proportion of the patients failed to complete their diaries for the full period of
